FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn Howie, Julia A. Beaver, Laleh Amiri‐Kordestani et al.|Clinical Cancer Research|2018Cited by 68